The Top 5 Biosimilars Articles for the Week of September 16

Transcript

Hi, I’m Jaime Rosenberg for The Center for Biosimilars^®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 16, 2019.

Number 5: Innovator drug maker Roche says that it plans to see substantial erosion of its sales of rituximab, trastuzumab, and bevacizumab products by 2023.

Number 4: The American College of Rheumatology says that a large proportion of patients with rheumatic diseases had difficulty accessing and paying for their therapies in the past year.

Number 3: The Biosimilars Council has issued part 2 of its recent white paper on barriers to biosimilars in the United States; the newly published segment highlights post-market challenges to biosimilar adoption.

Number 2: A recent study says that step therapy in rheumatoid arthritis or psoriatic arthritis can hurt treatment outcomes.

Number 1: The United States Court of Appeals for the Third Circuit sided with Johnson & Johnson, requiring a dispute between the drug maker and Rochester Drug Cooperative to be sent to arbitration.

Finally, last week, our e-newsletter asked whether you think that Europe’s biosimilars market faces challenges to sustainability.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.